About Elucid
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid equips physicians with critical information designed to enable precision medicine. Elucid is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The Elucid software is available for commercial use in the U.S. and Europe
|
|
|
51-200 employees
View all Elucid employees
|
|
Medical Devices
|
|
2 Park Plaza, 700, Boston, Massachusetts 02116, US
|
|
2013
|
|
Cardiovascular, Heart Disease, Ccta, Ct Aniography, Ffrct, Plaque Characterization
|
Elucid Alternatives
Frequently Asked Questions about Elucid
The decision makers in Elucid are Amy Kruglak, Blake Richards, Blake Richards, etc. Click to Find Elucid decision makers emails.
Elucid Staff Directory
Search Elucid Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
